NCT02182440已完成2 期
A DB Four-Arm, Parallel Group, Proof of Concept, Dose-Finding Adaptive Phase 2a/2b RCT to Investigate the Safety, Tolerability and Efficacy and Effect on QoL of Human Recombinant Alkaline Phosphatase in Patients With Sepsis-Associated AKI
AM-Pharma58 个研究点 分布在 11 个国家目标入组 301 人开始时间: 2014年12月18日最近更新:
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 301
- 试验地点
- 58
- 主要终点
- Area Under the Time Corrected Endogenous Creatinine Clearance From Day 1 to Day 7 (AUC1-7)
研究概览
简要总结
The purpose of this study is to determine whether recombinant Alkaline Phosphatase (recAP) is effective and save, and to determine the most effective dose, in the treatment of patients with acute kidney injury caused by sepsis.
详细描述
Design:
Adaptive trial with two stages and interim analysis
- Stage 1: four arms; three dose groups and placebo. n=30/arm. (n=120)
- Interim analysis based on 120 subjects, with continued recruitment, adding 11 subjects to Stage 1 safety population (n=131): to evaluate safety and select dose for stage 2
- Stage 2: one dose group and placebo. N=85/arm. (n=170) Total n in the study: 301.
Primary objectives
- To investigate the effect of recAP on renal function (measured creatinine clearance D1-D7 period, incidence and duration of renal replacement therapy (RRT) over 28 days, eGFR at D60 and D90) and related clinical parameters (ICU stay, Hospital stay, Mechanical ventilation over 28 days, SOFA and SAPS2 scores 28 days) in patients with SA-AKI.
- To determine effective therapeutic dose(s) of recAP.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed Informed Consent Form (patient, legal representative or independent investigator)
- •Age 18 to 85 years, inclusive
- •Is admitted to the ICU or Intermediate Care Unit
- •Has diagnosis of sepsis (< 96 hrs prior to first study drug), according to criteria defined by the American College of Chest Physicians/Society of Critical Care Medicine:
- •Has a proven or strongly suspected bacterial infection.
- •Has at least 2 of 4 SIRS criteria 72 hrs < screening and 96 hrs < first study drug
- •First diagnosis of AKI: AKI Stage 1 or greater, according to the AKIN criteria (time-window adjusted):
- •Increase in serum creatinine > 26.2 µmol/L (0.30 mg/dL) in 48 hrs prior to screening, or
- •Increase in serum creatinine to > 150% (> 1.5-fold) from reference creatinine value in 48 hrs prior to screening
- •Urinary output < 0.5 mL/kg/h for > 6 hours following adequate fluid resuscitation
- •Continuing AKI needs to be confirmed by a confirmative fluid corrected serum creatinine measure, or
- •When the AKI diagnosis was made according to the AKIN urine output criteria (urinary output < 0.5 mL/kg/h for > 6 hours), the oliguria or anuria should still meet the AKIN urine output criteria prior to randomization.
排除标准
- •Woman of childbearing potential with a positive pregnancy test, pregnant, or breastfeeding.
- •Weighs more than 115 kg (253 lb).
- •Has life support limitations.
- •Is known to be human immunodeficiency virus positive.
- •Has urosepsis.
- •Is already on dialysis (RRT) or anticipated to receive RRT within 24 hours after study drug dosing due to the underlying disease.
- •Is receiving immunosuppressant treatment or is on chronic high doses of steroids equivalent to prednisone/prednisolone 0.5 mg/kg/day, including solid organ transplant patients. Patients with septic shock treated with hydrocortisone (e.g., 3 × 100 mg) can be included.
- •Is expected to have rapidly fatal outcome (within 24 hours).
- •Has known, confirmed fungal sepsis.
- •Has advanced chronic liver disease, confirmed by a Child-Pugh score of 10 to
- •Has acute pancreatitis with no established source of infection.
- •Has participated in another investigational study within 30 days prior to enrollment.
- •Is not expected to survive for 28 days due to medical conditions other than SA AKI, including cancer, end-stage cardiac disease, cardiac arrest requiring cardiopulmonary resuscitation or with pulseless electrical activity or asystole within the past 30 days, end stage lung disease, and end stage liver disease.
- •Has known prior history of Chronic Kidney Disease with a documented estimated Glomerular Filtration Rate (eGFR) < 60 mL/min by Modification of Diet in Renal Disease MDRD or CKD-EPI formula, known GFR < 60 mL/min, or a known history of persistent creatinine level > 150 µmol/L (1.70 mg/dL) for reasons other than the current sepsis condition.
- •Has diagnosis of malaria or other parasite infections.
- •Has burns on > 20% of body surface.
- •Has had AKI diagnosis according to inclusion criteria > 24 hours prior to study drug administration.
- •Is anticipated to be treated with non-continuous RRT from Day 1 to Day
- •During Day 1 to Day 7 continuous RRT is anticipated to be started or stopped not according to per protocol criteria.
- •The AKI is most likely attributable to other causes than sepsis, such as nephrotoxic drugs and renal perfusion-related.
- •Improvement in serum creatinine of at least 0.30 mg/dL or (26.2 µmol/L) prior to administration of the study drug.
- •Patients who use nephrotoxic medication and who fulfill the SA-AKI inclusion criteria at screening are not eligible if the use of this nephrotoxic medication is to continue when alternative, medically appropriate, non-nephrotoxic medication is available.
- •Has a history of known IV drug abuse.
- •Is an employee or family member of the investigator or study site personnel.
- •Has active hematological malignancy.
研究组 & 干预措施
Placebo
Placebo Comparator
1 hour IV infusion once daily for 3 days
干预措施: Placebo (Other)
1.6 mg/kg (1000 U/kg) recAP
Experimental
1 hour IV infusion once daily for 3 days
干预措施: recAP (Biological)
0.8 mg/kg (500 U/kg) recAP
Experimental
1 hour IV infusion once daily for 3 days
干预措施: recAP (Biological)
0.4 mg/kg (250 U/kg) recAP
Experimental
1 hour IV infusion once daily for 3 days
干预措施: recAP (Biological)
结局指标
主要结局
Area Under the Time Corrected Endogenous Creatinine Clearance From Day 1 to Day 7 (AUC1-7)
时间窗: 7 days
Primary endpoint is calculated as the average of the standardized endogenous creatinine clearance values over the first seven days between the placebo and 1.6 mg/kg recAP arm. Standardized endogenous creatinine clearance is assessed on each days from D1 to Day 7 during a 6 +/- 1 hour period and calculated in mL/min as the mean creatinine clearance over the period. The study started with 4 treatment arms of which 0.4 mg/kg recAP and the 0.8 mg/kg recAP were dropped after the interim analysis. The number of the patients in the dropped arm are respectively 30 and 32. Therefore the statistical analysis has been performed only on the placebo and 1.6 mg/kg group.
次要结局
- Number of Participants Who Had Renal Replacement Therapy (RRT) During the Period Day 1 to Day 28, Inclusive(28 days)
研究者
研究点 (58)
Loading locations...
相似试验
已完成
不适用
Effects of Soluble Phosphate in HumansHealthy VolunteersNCT02095392University of Jena62
尚未招募
3 期
Comparing Alkaline Phosphatase and Cathepsin-B Levels in Gum Fluid including the participants with misaligned teeth During Orthodontic Interventions with Self-Ligating Brackets, Conventional Brackets, and AlignersCTRI/2024/06/068338SELF
已完成
1 期
Microdose and First-In-Human (FIH) Study of Recombinant Human Placental Alkaline Phosphatase (hRESCAP)HealthyNCT01889147TNO4
已完成
不适用
Efficiency of PRP on Acellular Dermal Matrix Application in the Treatment of Multiple Adjacent Gingival RecessionsGingival Recession, GeneralizedNCT03043638Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization12
尚未招募
Unknown
Serum Alkaline Phosphatase and outcome in ARDS Patients A retrospective observational studyAcute respiratory distress syndrome and serum alkaline phosphataseJPRN-UMIN000051190Faculty of medicine Menofia university, Egypt60